



Cite this: DOI: 10.1039/d5sc05555e

All publication charges for this article have been paid for by the Royal Society of Chemistry

Unconventional chalcogen-containing azolydene metal complexes as potential anticancer therapeutics

Jan Romano-deGea,^{ID}*^a Irina L. Sinenko,^{ID}^a Peter M. F. Pânzar,^{ID}^a Adriana Neves Vieira,^{ID}^a Lindsey E. K. Frederiksen,^{ID}^a Kseniya Glinkina,^{ID}^a Farzaneh Fadaei-Tirani,^{ID}^a Rosario Scopelliti,^{ID}^a Fabien Kuttler,^{ID}^b Kelvin Lau^{ID}^c and Paul J. Dyson^{ID}*^a

Organometallic compounds with N-heterocyclic carbene (NHC) ligands have been studied for their anticancer and antimicrobial properties, with imidazole and benzimidazole derivatives being the predominant scaffolds for potential NHC-containing drugs. In contrast, chalcogen-containing azolydene ligands, (N,Y)HCs (Y = O, S, Se), remain largely unexplored in both medicinal inorganic chemistry and, more generally, in inorganic chemistry. Consequently, to study the effect of the incorporation of a chalcogen atom in the ligand, classical (N,N)HC complexes of platinum, gold and ruthenium were selected based on their previously reported biological activity and proposed mechanisms of action, and their (N,Y)HC (Y = O, S, Se) analogues were synthesised. The electronic and steric properties of the ligands and complexes were explored and their biological activity was evaluated. The introduction of a chalcogen atom within the heterocyclic scaffold of the ligands was found to modulate their interaction with biomolecules and regulate the cytotoxicity of the metal complexes towards ovarian cancer cells.

Received 24th July 2025
Accepted 28th December 2025

DOI: 10.1039/d5sc05555e

rsc.li/chemical-science

Introduction

N-heterocyclic carbene (NHC) metal complexes display remarkable stability and tuneability, which explains their widespread use in many areas of chemistry.^{1,2} In recent years, NHC complexes, in particular platinum, gold, and ruthenium compounds, have been evaluated as anticancer, antimicrobial, antiviral and antiparasitic agents.^{3–7}

Platinum-NHC complexes display cytotoxic effects comparable, or superior, to cisplatin against a variety of cancer cell lines.⁸ Traditionally, the mechanism of action (MoA) of platinum-based anticancer compounds has been related to their ability to bind the minor groove of DNA to then form 1,2-intrastrand crosslinks between nucleobases, blocking the translation and replication of DNA.⁴ In contrast, due to geometric constraints, *trans*-(NHC)PtX₂(amine) complexes presumably form long-range DNA intra- and inter-strand adducts.^{9,10} These alternative crosslinks are less likely to be recognised as defects by repair proteins

in cisplatin-resistant tumours.¹¹ Therefore, such complexes are more likely to be active against cisplatin-resistant cell lines.¹²

In comparison, gold-NHC complexes are reported to inhibit proteins, such as thioredoxin reductase (TrxR), an enzyme overexpressed in some solid tumours.^{13,14} TrxR inhibition is associated with inhibition of mitochondrial respiration, potentially inducing apoptosis *via* mitochondria-mediated pathways.^{15,16} Furthermore, gold-NHC complexes tend to display high antiproliferative activity.^{4,13,17}

Ruthenium-NHC complexes have been reported as inhibitors of cysteine- and selenocysteine-containing biomolecules, including TrxR and cathepsin B (CatB).¹⁸ The latter is a cysteine protease for which elevated expression levels are often associated with the progression of various tumours.¹⁹ Additionally, (*p*-cymene)(NHC)RuCl₂ complexes act as antiproliferative agents, with IC₅₀ values frequently in the low micromolar range.^{20,21}

The modulation of the biological properties of metal NHC complexes is usually achieved through structural modifications introduced on the nitrogen atoms, also known as wingtips, or through the substituents on the heterocyclic backbone.^{4,5} Other carbene ligand classes such as triazoles and cyclic(alkylamino) carbenes (cAACs) have also been employed as scaffolds in medicinal inorganic chemistry.^{22,23} In contrast, metal complexes with chalcogen-containing azolydene ligands, (N,Y)HCs (Y = O, S, Se), are rare,²⁴ and studies of their biological properties are very scarce.^{25,26} In particular, only a single selenium-containing carbene metal complex has been previously reported.²⁷ The effect on the

^aInstitute of Chemical Sciences and Engineering, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland. E-mail: jan.romanodegea@epfl.ch; paul.dyson@epfl.ch

^bBiomolecular Screening Facility, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland

^cProtein Production and Structure Core Facility, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland




Fig. 1 Selected parent (N,N)HC metal complexes (a) and their azolyldene (N,Y)HC ($Y = \text{NR}, \text{S}, \text{O}, \text{Se}$) analogues (b).


biological activity of substituting the nitrogen atom in (N,N)HC ligands by a chalcogen atom remains, to the best of our knowledge, unexplored. (N,Y)HC ($Y = \text{O}, \text{S}, \text{Se}$) ligands present different steric and electronic properties compared to their classical nitrogen-containing counterparts. The chalcogen atoms are not alkylated, and hence they are more exposed than nitrogen atoms in (N,N)HCs, resulting in the characteristic “missing-wingtip” shape of these ligands.²⁸ The metal atoms are also more exposed, albeit to a lesser extent. Besides modulating the electron donating abilities, the chalcogen atoms affect the aromaticity of the heterocycles.²⁹ The chalcogen atoms in the azolyldene ligands have lone pairs that can act as acceptors in hydrogen bonds (HBs).^{29–31} Additionally, sulphur- and selenium-containing molecules can form intra- and intermolecular chalcogen bonds (ChBs).³¹ The presence of these interactions has ramifications in a wide range of fields and applications, including catalysis and biology, particularly in substrate and ligand–protein binding.^{32–36}

To explore the effect of the introduction of a chalcogen atom to the cytotoxicity and to evaluate structure–activity relationships (SAR) in unconventional chalcogen azolyldene metal complexes, four parent (N,N)HC metal complexes were selected based on reported examples in the literature demonstrating considerable cytotoxic effects and with a hypothesis on the mechanism of action (Fig. 1a): two *trans*-(NHC)Pt₂(amine) complexes bearing non-fused 1,3-dimethylimidazolyldene or 1,3-dibenzylimidazolyldene ligands (**Pt1^{NMe}** and **Pt2^{NBn}**) capable of overcoming cisplatin-acquired resistance;¹² a highly antiproliferative TrxR inhibitor gold(i) iodido complex bearing a benzoannulated 1,3-diethylbenzimidazolyldene ligand (**Au3^{NEt}**);³⁷ and a ruthenium cymene complex bearing a fused 1,3-dibenzylbenzimidazolyldene ligand (**Ru4^{NBn}**) with TrxR and CatB inhibition properties.³⁸ Their azolyldene analogues were successfully synthesised (Fig. 1b) and their biological behaviour was evaluated.

Results and discussion

Synthesis and characterisation

The non-fused and benzoannulated azolium (N,Y)HC proligands, **1^Y·HX–4^Y·HX** ($Y = \text{NR}, \text{O}, \text{S}$ or Se ; $X = \text{halide}$), were



Scheme 1 Synthesis of **Pt1^Y** and **Pt2^Y** ($Y = \text{NR}, \text{S}$) (a) and **Pt1^O** and **Pt2^O** (b).

prepared in one step by heating the appropriate azole in acetonitrile (or neat) with the corresponding alkyl or benzyl halide to obtain the desired products in good to excellent yields. The azolium salts are hygroscopic and, in some cases, deliquescent. Therefore, special care should be taken with their isolation, purification and storage. The yields of the oxazolium salts are consistently lower than the others due to their tendency to ring open when exposed to heat, moisture or basic conditions.³⁹ The corresponding (N,Y)HC metal complexes were synthesised using either silver transmetalation or a weak base as described previously.^{1,24,40,41} All compounds were characterised by ¹H and ¹³C NMR spectroscopy and high-resolution mass spectrometry (HRMS).

Platinum (N,Y)HC complexes

Complexes **Pt1^Y** ($Y = \text{NMe}, \text{S}$) and **Pt2^Y** ($Y = \text{NBn}, \text{S}$) were synthesised in one step using a slightly modified literature procedure (Scheme 1a).⁴² The respective proligands (**1^Y·HI** and **2^Y·HBr**), PtCl₂, K₂CO₃ (the base required to deprotonate the carbene precursors), and NaI (as the iodide source) were heated under reflux in pyridine (acting as both the solvent and ligand). When applying these conditions to the synthesis of **Pt1^O** and **Pt2^O**, only *trans*-[Pt(py)₂I₂] was isolated from the mixtures, and ring opening of the oxazolium salts was observed by ¹H NMR spectroscopy.³⁹ Instead, in order to obtain **Pt1^O** and **Pt2^O**, *trans*-[Pt(pyridine)(dmsO)₂I₂] was reacted in DCM with the corresponding oxazolium salt in the presence of potassium acetate (KOAc), a weaker base, to yield the desired products in acceptable yields (Scheme 1b).

The desymmetrisation of the (N,Y)HC ligand by the introduction of the chalcogen atom is apparent in the ¹H NMR spectra of **Pt1^Y** and of **Pt2^Y** ($Y = \text{NR}, \text{O}, \text{S}$). One signal is present for the protons in the heterocyclic backbone in **Pt1^{NMe}** and **Pt2^{NBn}**, whereas two distinct signals are observed in **Pt1^Y** and **Pt2^Y** ($Y = \text{O}, \text{S}$) (SI Fig. 1). No major differences were observed in the ¹H NMR spectra for the peaks corresponding to the pyridine ligand. The ¹⁹⁵Pt NMR chemical shift of **Pt1^Y** and **Pt2^Y** ($Y = \text{NR}, \text{O}, \text{S}$) ranges between –4100 and –4400 ppm, in keeping with previous reports on platinum(II) (N,N)HC complexes.⁴³ The introduction of the chalcogen atom into the carbene ligands leads to a slight upfield shift of the ¹⁹⁵Pt NMR signals of **Pt1^O** and **Pt2^O** compared to **Pt1^{NMe}** and **Pt2^{NBn}**, whereas






Fig. 2 Single-crystal XRD structures of **Pt1^O** (a) and **Pt1^S** (b). Thermal ellipsoids are drawn with a 50% probability. Symmetry elements have been omitted for clarity. The structures of **Pt1^{NMe}** and **Pt2^{NBn}** can be found in SI Fig. 4.

a considerable downfield shift is observed for **Pt1^S** and **Pt2^S**. The upfield shift is indicative of a more electron-rich metal centre, due to a more electron-donating and less π -accepting ligand.^{44,45} Therefore, it could be expected that the carbene ligands in **Pt1^O** and **Pt2^O** form weaker bonds with the Pt(II) centre.


Crystals suitable for single-crystal X-ray diffraction (scXRD) were grown for **Pt1^{NMe}**, **Pt1^O**, **Pt1^S** and **Pt2^{NBn}** (see Fig. 2 and SI Fig. 4a and b). The structures confirmed the presence of the coordinated (N,Y)HC ligands and of the expected *trans*-configuration. In **Pt1^Y** (Y = NMe, O, S), the Pt–C_{NYHC} bond length decreases from **Pt1^O** to **Pt1^{NMe}** and then to **Pt1^S** (Table 1), consistent with the ¹⁹⁵Pt NMR chemical shift. Additionally, the (N,Y)HC ligands in **Pt1^O** and **Pt1^S** are slightly tilted with respect to the platinum atom (172.2° and 174.5°, respectively), deviating from the ideal “linear” structure observed in **Pt1^{NMe}** and **Pt2^{NBn}** (180°). Presumably, the elongated Y–C_{NYHC} (Y = O, S) bond results in the distorted geometries. All other bonds and angles are within the expected ranges.

Gold (N,Y)HC complexes

Au3^{NEt}, **Au3^S** and **Au3^{Se}** were prepared from the reaction between the corresponding proligand, Au(SMe₂)Cl, and K₂CO₃ in acetone at 60 °C (Scheme 2).⁴¹ A modified approach, using KOAc in place of K₂CO₃, was employed in the preparation of the oxazolyldene complex **Au3^O**, to avoid the ring opening of the (N,O)HC ligand.

Table 1 Selected bond lengths (Å) and angles (°) for **Pt1^{NMe}**, **Pt1^O**, and **Pt1^S**

	Pt1^{NMe}	Pt1^O	Pt1^S
Pt–C _{NYHC}	1.961(5)	2.079(18)	1.948(7)
Pt–N _{Pyr}	2.082(4)	1.960(18)	2.071(5)
Pt–I _{avg}	2.5935(3)	2.5953(21)	2.5932(3)
NR–C _{NYHC}	1.347(5)	1.37(3)	1.251(11)
Y–C _{NYHC}	1.347(5)	1.31(3)	1.801(5)
C _{NYHC} –Pt–N _{Pyr}	180.0	178.07(7)	180.0
NR–C _{NYHC} –Y	105.1(5)	107(2)	106.8(7)
NYHC centroid–C _{NYHC} –Pt	180.0	172.2	174.5
NYHC–Pyr	35.7	11.9	22.2



Scheme 2 Synthesis of **Au3^Y** (Y = NEt, O, S, Se).




Fig. 3 Single-crystal XRD structures of **Au3^O** (a) and **Au3^S** (X = Br) (b). Thermal ellipsoids are drawn with a 50% probability. The structure of **Au3^{NEt}** can be found in SI Fig. 4.



The benzothiazole peaks split in the ¹H NMR spectra of **Au3^O** due to the desymmetrisation of the ligand, and become fully resolved in **Au3^S** and **Au3^{Se}** (SI Fig. 2). Additionally, the ethyl “wingtips” peaks shift downfield, indicating a more deshielded environment due to the introduction of the chalcogen atom or close proximity to the metal due to the lower steric hindrance. As observed in the platinum complexes, the Au–C_{NYHC} bond length in the single-crystal structures decreases from **Au3^O** to **Au3^{NEt}** and then to **Au3^S** (Fig. 3, Table 2, and SI Fig. 4c). Similarly, the (N,Y)HC ligands in **Au3^O** and **Au3^S** are slightly tilted with respect to the gold atom compared to the ideal structure in **Au3^{NEt}** (173.0° and 174.5°, respectively, vs. 180°). All other bonds and angles are within the expected ranges.

Ruthenium (N,Y)HC complexes

Ru4^{NBn} was synthesised in two steps using a transmetalation route from a silver-(N,N)HC intermediate.⁴⁶ As the isolation of the silver-(N,S)HC and silver-(N,Se)HC intermediate was unsuccessful, a previously reported one-pot route was employed to obtain **Ru4^S** and **Ru4^{Se}** (Scheme 3).⁴⁷ Unfortunately, the synthesis of **Ru4^O** was unsuccessful both *via* the one-step or two-step transmetalation routes, as well as by using the weak base

Table 2 Selected bond lengths (Å) and angles (°) for **Au3^{NEt}**, **Au3^O**, and **Au3^S**

	Au3^{NEt}	Au3^O	Au3^S (X = Br)
Au–C _{NYHC}	2.008(10)	2.05(4)	1.981(3)
Au–X	2.5449(8)	2.556(3)	2.4023(3)
NR–C _{NYHC}	1.330(8)	1.33(5)	1.331(4)
Y–C _{NYHC}	1.330(8)	1.35(5)	1.718(3)
C _{NYHC} –Au–X	180.0	174.7(11)	176.45(8)
NR–C _{NYHC} –Y	107.8(8)	110(3)	110.4(2)
NYHC centroid–C _{NYHC} –Au	180.0	173.0	174.5

Scheme 3 Synthesis of Ru4^Y (Y = NBn, S, Se).Fig. 4 Single-crystal XRD structures of Ru4^S (a), and Ru4^{Se} (b). Thermal ellipsoids are drawn with a 50% probability. Solvates have been omitted for clarity. The structure of Ru4^{NBn} can be found in SI Fig. 4.

(KOAc) route.⁴¹ A similar approach to the synthesis of **Pt1^O** or **Pt2^O** was also attempted, using KOAc and a ruthenium complex bearing a labile ligand, (η^6 -*p*-cymene)RuCl₂(DMSO). However, the (N,O)HC ruthenium complex was not isolated.

The rotation of the Ru–C_{NYHC} bond is restricted in **Ru4^{NBn}**, with the benzylic N–CH₂–Ph ¹H NMR peaks appearing as two coupling doublets (at 5.84 and 6.56 ppm). In contrast, these peaks converge into singlets in **Ru4^S** and **Ru4^{Se}** (at 6.36 and 6.37 ppm, respectively), suggesting that the carbene is able to freely rotate (SI Fig. 3). Single-crystals of **Ru4^Y** (Y = NBn, S, Se) suitable for scXRD were grown (Fig. 4, Table 3 and SI Fig. 4d). To the best of our knowledge, the structure of **Ru4^{Se}** is the first example of a selenazolyliene complex to be reported. Only one other selenium-containing carbene complex has been previously reported, *i.e.* a chromium(0) (arylseleno)(diethylamino) carbene Fischer complex.²⁷ **Ru4^{Se}** features a central Ru(II) ion in the typical distorted pseudo-octahedral geometry of piano-stool complexes also exhibited by **Ru4^{NBn}** and **Ru4^S**. The ruthenium


atom is coordinated by two chlorido ligands, an η^6 -bound cymene ligand and **4^{Se}**, a selenium-containing (N,Se)HC ligand. The C_{NYHC}–Se distance is 1.875(3) Å and the N–C_{NYHC}–Y angle is 109.5(2)°. All other bonds and angles are within range of the values previously reported in Ru(II)-arene NHC complexes. The crystal packing is stabilised by π – π stacking of adjacent benzoselenazolyliene rings. Close Cl...H contacts may contribute to the packing stability, and a close contact between the selenium atom and the oxygen atom in THF is also observed ($d_{\text{Se} \cdots \text{O}} = 3.157$ Å and $\theta_{\text{C-Se-O}} = 162.6^\circ$), constituting evidence of a ChB.⁴⁸ The Ru–C_{NYHC} bond length decreases from 2.097(7) Å in **Ru4^{NBn}** to 2.038(2) and 2.032(2) Å in **Ru4^S** and **Ru4^{Se}**, respectively, indicating that the interaction between the metal and the (N,Y)HC ligands might be stronger.

Electronic and steric analysis of the ligands and complexes

The electronic and steric properties of **1^Y–4^Y** (Y = NR, O, S, Se) were evaluated.⁴⁹ The net electronic influence was assessed using Tolman electronic parameter (TEP) values, further separated into the σ -donating ability and π -accepting contributions by analysing the one-bond coupling constant, ¹J_{CH}, of the carbene carbon atom in the ¹H NMR of the azolium salts and the ⁷⁷Se NMR chemical shift, δ_{Se} , of the selenium adducts.⁵⁰ Additionally, DFT calculations were performed to support the experimental findings.⁵¹ Experimental TEP (TEP_{exp}) were determined from the CO stretching frequencies of Rh[(N,Y)HC](CO)₂Cl, **Rh1^Y–Rh4^Y** (Fig. 5a), with the donor ability of the carbene atom following the trend, N >> O > S > Se. The σ -donor strength was extracted from the one-bond coupling constant, ¹J_{CH}, of the carbene atom of **1^Y·HX–4^Y·HX** (Y = NR, O, S or Se; X = halide) in *d*₆-DMSO.^{52,53} The extent of σ -donation of the ligands is slightly lower in (N,O)HCs than in classical (N,N)HCs, whereas (N,S)HCs and (N,Se)HCs are slightly stronger σ -donors (SI Fig. 5a). The π -backbonding properties were assessed using a method based on the ⁷⁷Se NMR chemical shift, δ_{Se} , of the selenium adducts **Se1^Y–Se4^Y** (Y = NR, O, S, Se).⁵⁴ Based on the magnitude of δ_{Se} , the π -accepting properties of the carbene ligands increases according to the following sequence N < O < S < Se (SI Fig. 5b). Calculated TEP values (TEP_{comp}), obtained from the analysis of the molecular electrostatic potential surface as reported previously, are in

Table 3 Selected bond lengths (Å) and angles (°) for Ru4^{NBn}, Ru4^S, and Ru4^{Se}

	Ru4 ^{NBn}	Ru4 ^S	Ru4 ^{Se}
Ru–C _{NYHC}	2.097(7)	2.038(2)	2.032(2)
Ru–Arene	1.699	1.702	1.705
Ru–Cl _{avg}	2.422(2)	2.412(9)	2.413(1)
NR–C _{NYHC}	1.359(8)	1.346(3)	1.338(3)
Y–C _{NYHC}	1.390(9)	1.725(2)	1.875(3)
C _{NYHC} –Ru–Arene	126.3	129.1	129.4
Cl ₁ –Ru–Cl ₂	84.32(6)	86.48(2)	86.89(2)
NR–C _{NYHC} –Y	105.6(5)	109.2(2)	109.5(2)
N–CH ₂ –Phenyl	86.6 ± 0.5	79.1	79.5
NYHC centroid–C _{NYHC} –Ru	178.5	176.2	175.0

Fig. 5 TEP_{exp} of carbene ligands **1^Y–4^Y** (Y = NR, O, S, Se) (a) and steric map of **Au3^Y** (Y = NEt, O, S, Se) showing total and per quadrant buried volume (%V_{bur}) (b).

agreement with the trend observed from the experimental data (SI Fig. 6a).⁵⁵ The HOMO and LUMO energy of 1^Y-4^Y ($Y = \text{NR, O, S, Se}$) correlate well with the experimentally measured σ -donating and π -accepting character of the ligands (SI Fig. 6b).⁵⁶ The electron occupancy in the $\text{M}-\text{C}_{\text{NYHC}}$ bond decreases in the order $(\text{N,O})\text{HC} > (\text{N,N})\text{HC} > (\text{N,Se})\text{HC} > (\text{N,S})\text{HC}$ (SI Table 8), in agreement with the ^{195}Pt NMR chemical shifts and crystallographically determined bond lengths.

The study of the electrostatic surface of the optimised 4^Y ($Y = \text{O, S, Se}$) structures reveals the presence of a highly polarised p-orbital shaped lone pair on the chalcogen atom and perpendicular to the ring (SI Fig. 7a). These lone pairs, which become more diffuse when descending Group 16, could engage in HB interactions. Furthermore, sigma-holes, which are directly related to the ChB ability of the molecules, are observed in 4^{S} and 4^{Se} (SI Fig. 7b and SI Table 6).³¹ The potential to form ChB is evidenced by the $\text{Se}-\text{O}$ close contact present in the crystal structure of $\text{Ru}4^{\text{Se}}$, which adheres to the crystallographic definition of a ChB.^{57,58}

Complementary to the electronic characterisation, the steric effects of the ligands were evaluated. The percentage of buried volume (V_{bur}) around the metal centre was estimated from the experimentally determined or optimised structures of $\text{Pt}1^Y$, $\text{Pt}2^Y$, $\text{Au}3^Y$, and $\text{Ru}4^Y$ ($Y = \text{NR, O, S, Se}$) (Fig. 5b and SI Fig. 10).⁵⁹ The total $\%V_{\text{bur}}$ decreases upon substitution of the alkylated nitrogen for a chalcogen, and then increases with the increasing atomic size of the Group 16 element, following the trend $\text{N} \approx \text{Se} < \text{S} < \text{O}$. Furthermore, the $\%V_{\text{bur}}$ in the chalcogen-containing quadrants display less buried volume, highlighting that the coordination sphere surrounding the metal is less sterically crowded in the $(\text{N,Y})\text{HCs}$ ($Y = \text{O, S, Se}$) complexes.^{28,60}

The steric and electronic analysis indicates that the unconventional azolyldiene carbenes ligands, 1^Y-4^Y ($Y = \text{NR, O, S, Se}$),

are stronger π -acceptor ligands than classical $(\text{N,N})\text{HCs}$ with similar σ -donation ability (with the exception of the oxazolyldienes). Furthermore, they present a less congested binding sphere and the incorporation of chalcogen atoms potentially enables HB and ChB interactions.

In vitro studies

The cytotoxicity of $\text{Pt}1^Y$, $\text{Pt}2^Y$, $\text{Au}3^Y$, and $\text{Ru}4^Y$ ($Y = \text{NR, O, S, Se}$) was evaluated against the A2780 ovarian cancer cell line, A2780cis cells with acquired resistance to cisplatin, and non-cancerous human embryonic kidney HEK293T cells (Table 4), using the PrestoBlue assay.⁶¹ FDA-approved drugs cisplatin and auranofin, and the experimental drug RAPTA-C were included as controls. Note that the cytotoxicity of proligands $1^Y \cdot \text{HX}-4^Y \cdot \text{HX}$ ($Y = \text{NR, O, S, Se; X} = \text{halide}$) is lower than that of the related complexes against the screened cell lines (SI Table 9). Complexes $\text{Pt}1^Y$ and $\text{Pt}2^Y$ ($Y = \text{NR, O, S}$) exhibit cytotoxicity values in the range of 0.6 to 30 μM against the ovarian cancer cell lines. Complexes based on the benzylazolyldiene scaffold, $\text{Pt}2^Y$ ($Y = \text{NBn, O, S}$), are more cytotoxic than the methylazolyldiene analogues, $\text{Pt}1^Y$ ($Y = \text{NMe, O, S}$), probably as a consequence of their higher lipophilicity or the presence of a benzyl moiety capable of intercalating DNA bases.^{65,66} In both these cell lines, the most cytotoxic complexes are $\text{Pt}1^{\text{NMe}}$ and $\text{Pt}2^{\text{NBn}}$ ($\approx 3 \mu\text{M}$ and $\approx 1 \mu\text{M}$, respectively). The toxicity of the complexes diminished when replacing the imidazole ring for an oxazole ($\text{Pt}1^{\text{O}}$ and $\text{Pt}2^{\text{O}}$, $\approx 10 \mu\text{M}$ and $\approx 5 \mu\text{M}$), and further decreased when exchanging the oxygen atom for a sulphur atom ($\text{Pt}1^{\text{S}}$ and $\text{Pt}2^{\text{S}}$, $\approx 15 \mu\text{M}$ and $\approx 8 \mu\text{M}$). Although less cytotoxic than cisplatin to the A2780 cell line, $\text{Pt}1^Y$ and $\text{Pt}2^Y$ ($Y = \text{NR, O, S}$) are able to overcome acquired cisplatin-resistance in the A2780cis cell line (resistance index, $\text{RI} = 1.0-2.4$ vs. 24.1 for cisplatin), indicating that they probably operate *via* a different MoA to cisplatin. In particular, $\text{Pt}2^{\text{NBn}}$ presents comparable efficacy and selectivity for cancer cells to cisplatin, while being much more effective in the cisplatin-resistant cell line ($1.2 \pm 0.1 \mu\text{M}$ vs. $8.4 \pm 4.6 \mu\text{M}$).

The gold complexes, $\text{Au}3^Y$ ($Y = \text{NMe, O, S, Se}$) have IC_{50} values in all three cell lines ranging from 0.1 to 6.4 μM , with the complexes having different behaviour depending on the cell line. In the ovarian cancer A2780 cell line, $\text{Au}3^{\text{Se}}$ ($0.1 \pm 0.1 \mu\text{M}$), $\text{Au}3^{\text{S}}$ ($0.2 \pm 0.1 \mu\text{M}$) and $\text{Au}3^{\text{O}}$ ($0.2 \pm 0.2 \mu\text{M}$) exhibit cytotoxicity comparable to auranofin ($0.1 \pm 0.1 \mu\text{M}$), whereas $\text{Au}3^{\text{NMe}}$ ($0.6 \pm 0.2 \mu\text{M}$) is less cytotoxic. In contrast, in the cisplatin-resistant cell line A2780cis, $\text{Au}3^{\text{Se}}$ ($0.2 \pm 0.1 \mu\text{M}$) has the lowest IC_{50} value, followed by $\text{Au}3^{\text{NMe}}$, $\text{Au}3^{\text{O}}$ and then $\text{Au}3^{\text{S}}$. With the exception of $\text{Au}3^{\text{NMe}}$ and $\text{Au}3^{\text{Se}}$ ($\text{RI} = 4.9$ and 3.4), the complexes did not overcome acquired cisplatin resistance ($\text{RI} = 20-31$), indicating that the MoA of $\text{Au}3^Y$ ($Y = \text{O, S}$) likely involves interactions with DNA (that would be more efficiently repaired in the cisplatin resistant cells and would result in lower cytotoxicity).

Compared to RAPTA-C, which is not cytotoxic *in vitro* ($\text{IC}_{50} > 100 \mu\text{M}$), but effective *in vivo*,^{64,67} $\text{Ru}4^Y$ ($Y = \text{NBn, S, Se}$) are considerably more cytotoxic, with IC_{50} values in a similar range to $\text{Pt}1^Y$ ($Y = \text{NMe, O, S}$), *i.e.* 0.6 to 30 μM in the three cell lines. $\text{Ru}4^{\text{Se}}$ is the most cytotoxic compound of the series in all three cell lines,

Table 4 IC_{50} values of $\text{Pt}1^Y$, $\text{Pt}2^Y$, $\text{Au}3^Y$, and $\text{Ru}4^Y$ ($Y = \text{NR, O, S, Se}$), cisplatin, auranofin, and RAPTA-C in A2780, A2780cis and HEK293T cell lines after 72 h evaluated using the PrestoBlue assay.⁶¹ Resistance index (RI)^a, and *n*-octanol/water partition coefficients ($\log P_{\text{OW}}$)

Compound	IC_{50} (μM) after 72 h				
	A2780	A2780cis	HEK293T	RI^a	$\log P_{\text{OW}}$
$\text{Pt}1^{\text{NMe}}$	2.9 ± 0.2	2.8 ± 0.7	4 ± 1	1.0	1.3 ± 0.6
$\text{Pt}1^{\text{O}}$	8 ± 2	16 ± 4	18 ± 6	2.0	1.0 ± 0.5
$\text{Pt}1^{\text{S}}$	13 ± 8	30 ± 29	47 ± 23	2.4	1.3 ± 1.1
$\text{Pt}2^{\text{NBn}}$	0.6 ± 0.2	1.2 ± 0.1	1.4 ± 0.1	1.9	2.1 ± 0.8
$\text{Pt}2^{\text{O}}$	4 ± 1	5 ± 2	6 ± 2	1.5	1.6 ± 0.2
$\text{Pt}2^{\text{S}}$	6 ± 1	12 ± 3	9 ± 2	2.2	1.8 ± 1.0
Cisplatin	0.4 ± 0.1	8 ± 5	1.5 ± 0.2	24.1	-2.19 (ref. 62)
$\text{Au}3^{\text{NMe}}$	0.6 ± 0.2	2.7 ± 0.1	2.1 ± 0.6	4.9	1.6 ± 1.1
$\text{Au}3^{\text{O}}$	0.2 ± 0.2	5 ± 2	1.0 ± 0.1	31.5	1.2 ± 0.4
$\text{Au}3^{\text{S}}$	0.2 ± 0.1	6.4 ± 0.4	1.9 ± 0.3	29.2	1.5 ± 0.1
$\text{Au}3^{\text{Se}}$	0.1 ± 0.1	0.2 ± 0.1	0.1 ± 0.1	3.4	1.4 ± 0.3
Auranofin	0.1 ± 0.1	1.9 ± 0.4	0.4 ± 0.1	20.6	1.6 (ref. 63)
$\text{Ru}4^{\text{NBn}}$	5.9 ± 1.0	12.8 ± 0.9	13 ± 2	2.2	2.7 ± 0.3
$\text{Ru}4^{\text{S}}$	10 ± 1	26 ± 5	20 ± 3	2.7	2.2 ± 0.2
$\text{Ru}4^{\text{Se}}$	3.8 ± 0.8	9 ± 3	5 ± 1	2.2	2.4 ± 0.7
RAPTA-C	$>100 \mu\text{M}$	$>100 \mu\text{M}$	$>100 \mu\text{M}$		-1.8 (ref. 64)

^a Resistance index (RI) = $(\text{IC}_{50} \text{ A2780cis} / \text{IC}_{50} \text{ A2780})$.



which was also observed in **Au3^{Se}**. Additionally, all the complexes are active against cisplatin-resistant cells (RI = 2.2–2.7).

The lipophilicity of the complexes **Pt1^Y**, **Pt2^Y**, **Au3^Y**, and **Ru4^Y** (Y = NR, O, S, Se) decreases with the introduction of the chalcogen atom (Table 4 and SI Table 6), with the (N,O)HCs complexes exhibiting the highest hydrophilic character, likely due to the formation of HBs with water. Although the cytotoxicity of some NHC complexes has been previously linked with their lipophilicity,⁶⁸ this does not appear to be the case for **Pt1^Y**, **Pt2^Y**, **Au3^Y**, and **Ru4^Y** (Y = NR, O, S, Se). SAR analysis (based on the experimental and computational data from this study) was performed to identify major chemical, physical, structural and electronic properties modulating the cytotoxicity of **Pt1^Y**, **Pt2^Y**, **Au3^Y** and **Ru4^Y** (Y = NR, O, S, Se). Notably, typical factors such as lipophilicity or aromaticity do not appear to affect the cytotoxicity of the complexes to a great extent (SI Fig. S13). Instead, cytotoxicity appears to be correlated with the charge at the metal, the energy of the σ -hole and lone pair energy, or the Y-C_{NH}C bond length, and inversely correlated with percentage of V_{bur} in the NR quadrant or the energy of the π -donor orbital. These properties are directly linked to the nature of the azolyldene ligand. Despite the potential interest in **Pt1^{Se}** and **Pt2^{Se}** given the high cytotoxicity exhibited by **Au3^{Se}** and **Ru4^{Se}**, we did not synthesise them due to stability and accessibility challenges of unsubstituted selenazoles.⁶⁹

The cytotoxicity of the platinum complexes, **Pt1^{NMe}** and **Pt2^{NBn}**, is similar to other previously reported *trans*-(NHC) PtX₂(amine) complexes (between 0.9 and 3.1 μM).¹² Additionally, similar to the platinum compounds in this study, some of the related complexes reported also overcome acquired cisplatin-resistance. The cytotoxicity of **Ru4^{NBn}** in A2780 cells is also comparable to those reported in the literature ($2.1 \pm 0.9 \mu\text{M}$ and $2.4 \pm 1.0 \mu\text{M}$ against MCF-7 breast adenocarcinoma and HT-29 colon carcinoma cells, respectively).³⁸ In contrast, a 10-fold increase in the toxicity is observed in **Au3^{NEt}** compared to the same complex bearing a chlorido ligand instead of an

iodido ligand ($0.6 \pm 0.2 \mu\text{M}$ vs. $6.4 \pm 2.0 \mu\text{M}$).³⁷ **Au3^S** demonstrated comparable activity to a previously-reported peptide-derivatised (N,S)HC gold complex in lung carcinoma (A549) ($\text{IC}_{50} = 0.4 \pm 0.01 \mu\text{M}$).²⁶ We were not able to find any reports of the cytotoxicity of (N,O)HC complexes or of (N,Se)HC complexes, which had remained unexplored until now.

Mechanistic studies

As previously mentioned in the introduction, the parent (N,N) HC complexes, **Pt1^{NMe}**, **Pt2^{NBn}**, **Au3^{NEt}**, and **Ru4^{NBn}**, were selected as they had demonstrated anticancer activity and a MoA had been proposed. Interactions with DNA were proposed for **Pt1^{NMe}** and **Pt2^{NBn}**,¹² whereas **Au3^{NEt}** and **Ru4^{NBn}** were reported to interact with thioredoxin reductase (TrxR) and cathepsin B (CatB).^{37,38}

The inhibitory effect of **Pt1^Y** and **Pt2^Y** (Y = NR, O, S) on DNA synthesis during cell proliferation was quantified *in cellulo* using an EdU incorporation assay and fluorescence cell microscopy (Fig. 6 and SI Fig. 12).⁷⁰ Gemcitabine, a clinically-approved DNA synthesis inhibitor,⁷¹ was used as a positive control (100% inhibition), and the cells treated with an equivalent amount of DMSO served as a negative control (“untreated”, 0% inhibition). Cisplatin and transplatin were included as references. DNA synthesis was blocked to various degrees in the cells treated with the different platinum complexes. As expected based on their structure and cytotoxicity, cisplatin was a better DNA synthesis inhibitor than transplatin (62% vs. 23%), and **Pt1^Y** (Y = NMe, O, S) displayed a lower degree of inhibition than **Pt2^Y** (Y = NBn, O, S), presumably as a consequence of the ability of the benzyl wingtip to intercalate DNA. In particular, **Pt2^{NBn}**, the compound with the highest cytotoxicity, inhibited DNA synthesis more effectively than cisplatin under the tested conditions and reached comparable inhibition to the positive control (gemcitabine, 100%). Overall, the extent of inhibition of DNA synthesis




Fig. 6 Fluorescence microscopy images of HELA cells treated with **Pt1^Y** and **Pt2^Y** (Y = NR, O, S), cisplatin, and transplatin (3 μM) and gemcitabine (1 μM) with the degree of inhibition of DNA synthesis indicated (bottom right). Cell nuclei were labelled with Hoechst 33342 (blue), and nuclei undergoing DNA synthesis with Edu-AlexaFluor-488 (green). Gemcitabine and DMSO were used as a positive (100%) and negative (0%) control, respectively.






Fig. 7 Inhibition of Cathepsin B (CatB) and Thioredoxin Reductase (TrxR) by Au3^{Y} (Y = NEt, O, S, Se) and Ru4^{Y} (Y = NBn, S, Se). 1 μM and 5 μM of Au3^{Y} , and 10 μM and 5 μM of Ru4^{Y} were used for the TrxR and CatB assay, respectively. The untreated control was used to normalise enzyme activity.

correlates well with the cytotoxicity of the complexes, suggesting that the inhibition of DNA synthesis, likely by the formation of non-classical DNA adducts, is a key MoA of Pt1^{Y} and Pt2^{Y} (Y = NR, O, S).

The inhibitory activity of Au3^{Y} (Y = NEt, O, S, Se) and Ru4^{Y} (Y = NBn, S, Se) against CatB and TrxR was studied in A2780 cells using commercially available assays (Fig. 7). Au3^{Y} (Y = NEt, O, S, Se) inhibit the enzymatic activity of TrxR but are inactive against CatB. However, the degree of inhibition does not correlate with the cytotoxicity of the complexes, which further highlights that Au3^{Y} (Y = O, S, Se) may have other molecular targets. It is worth noting that other gold complexes, such as auranofin, have promiscuous multi-target activity.^{72,73} In contrast, Ru4^{Y} (Y = NBn, S, Se) are inactive for TrxR, whereas Ru4^{Y} (Y = NBn, Se) inhibit CatB activity, correlating well with their cytotoxicity and indicating that cathepsin B is a likely biological target of Ru4^{Y} (Y = NBn, Se), although other targets cannot be excluded.⁷⁴

Structural studies

Crystals of adducts between Ru4^{Y} (Y = S, Se) and hen egg white lysozyme (HEWL), a model protein, were obtained by crystal soaking and analysed by single-crystal X-ray diffraction (Fig. 8). Both crystals presented anomalous electron density around Asp101, where the ruthenium atoms and some of the Ru4^{Y} (Y = S, Se) ligands were modelled.

The ruthenium centre is coordinated in a bidentate fashion to the carboxylic acid of Asp101. The average Ru–O_{Asp101} bond length is 2.227 and 2.152 Å for Ru4^{S} and Ru4^{Se} , respectively, indicating that Ru4^{Se} might bind the protein more strongly. It is




Fig. 8 Binding sites of Ru4^{S} (a) and Ru4^{Se} (b) with HEWL (see SI for details).

conceivable that binding of Ru4^{S} to CatB is also weaker than that of Ru4^{Se} , which might explain the weaker CatB inhibition exhibited by Ru4^{S} (Fig. 7), also supported by the electronic description of 4^{S} as a weaker π -acceptor. In both structures, the (N,Y)HC ligand remains coordinated to the metal centre, but the arene and chlorido ligands have been substituted by solvent molecules and by the oxygen atoms in Asp101. The Ru–C_{NYHC} distance in the protein crystals adducts is 1.987 and 1.990 Å for Ru4^{S} and Ru4^{Se} , respectively, slightly shorter than in the intact Ru4^{S} and Ru4^{Se} structures (2.038(2) and 2.032(2) Å, respectively). In both crystallised adducts, the metal drug fragments have an occupancy of 1.0, and no further additional isomers were observed. A comparison of the ruthenated HEWL structures to the native protein crystals (PDB:4NHI) revealed no major structural perturbations (RMSD of 0.920 and 0.894 Å).

Presumably, the binding in Ru4^{Y} (Y = S, Se) is driven by the electrostatic interactions between the resulting cationic complex from the substitution of the chlorido ligands in Ru4^{Y} (Y = S, Se) and the negatively charged catalytic site of HEWL. It should be noted that the different soaking times (5–10 s vs. 3 days) could affect the binding sites. Other ruthenium complexes have been shown to interact with Asp101 in HEWL, however, only as naked ruthenium ions.^{75,76} Crystals of adducts between HEWL and dichloro(1,3-dimethylbenzimidazol-2-ylidene)(η^6 -*p*-cymene)ruthenium(II), a complex related to Ru4^{NBn} , revealed His15 and Lys33 as the preferred binding sites.⁷⁵ Hence, replacement of the nitrogen atom for a chalcogen atom in Ru4^{Y} (Y = NBn, S, Se) modulates the preferential binding site of the ruthenium complexes, likely a consequence of the more electron-poor ruthenium centres. Previously, other (N,N)HC ruthenium complexes have been reported to bind to both nitrogen- and oxygen-containing residues in several proteins,^{77–80} as well as to interact with carboxylic acid-containing amino acid residues.⁸¹

In order to elucidate the molecular interaction between the complexes and their studied biological targets, molecular docking was employed. However, the prediction of the binding site of metal complexes is non-trivial due to the reactivity of metal complexes with respect to nucleophiles (for example, water, amino acids, or nucleobases) and the scarcity of force fields able to describe metal atoms. Several solutions have been reported or adapted to address this challenge.^{82–85} We developed and validated an approach to the docking of metal-containing compounds based on Autodock⁸⁶ (see SI for the further details and discussion). The developed protocol yields reasonable redocking results in terms of the prediction of the metal binding site, and of the position, orientation, and conformation of the ligands.

Blind molecular docking (the whole biomolecule structure is used without any bias towards specific binding sites) was performed using the approach to evaluate potential binding sites and affinities of Pt1^{Y} and Pt2^{Y} (Y = NR, O, S) to DNA (from a simulated *trans*-bound DNA interstrand adduct),⁸⁷ of Au3^{Y} (Y = NEt, O, S, Se) to TrxR (PDB:2J3N),⁸⁸ and of Ru4^{Y} (Y = NBn, S, Se) to CatB (PDB:3AI8).⁸⁹

Pt1^{Y} and Pt2^{Y} (Y = NR, O, S) formed N7-guanine interstrand DNA adducts (SI Fig. 17, 18 and SI Table 12). The binding



energies for $\text{Pt}2^{\text{Y}}$ ($\text{Y} = \text{NBn}, \text{O}, \text{S}$) were lower than for $\text{Pt}1^{\text{Y}}$ ($\text{Y} = \text{NMe}, \text{O}, \text{S}$), consistent with the higher cytotoxicity and higher degree of inhibition of DNA synthesis (Fig. 6) exhibited by $\text{Pt}2^{\text{Y}}$ ($\text{NBn}, \text{O}, \text{S}$), arising from the additional π - π interactions between the benzyl group and the nucleobases (SI Fig. 18). Both chalcogen atoms in $\text{Pt}2^{\text{O}}$ and $\text{Pt}2^{\text{S}}$ are positioned towards a hydrogen bond donor area around the amine group of an adjacent adenine, which likely establishes a HB and stabilises the conformation.

Despite predicting binding sites for $\text{Au}3^{\text{Y}}$ ($\text{Y} = \text{NEt}, \text{O}, \text{S}, \text{Se}$) not typically linked to TrxR inhibition (Sec498),¹⁴ a HB was observed $\text{Au}3^{\text{O}}$ between the oxygen atom in the oxazolyldiene ligand and the amine of Lys67 (3.01 Å, SI Fig. 18). This was not observed in $\text{Au}3^{\text{S}}$ or $\text{Au}3^{\text{Se}}$, consistent with the expected strength of the HB (SI Table 4). In contrast, a ChB was present between the carbonyl oxygen in Thr58 and the chalcogen atom in $\text{Au}3^{\text{S}}$ or $\text{Au}3^{\text{Se}}$ (3.60 Å and 3.39 Å, SI Fig. 18). These results highlight that HB and ChB interactions are likely to occur in (N,O)HC, and in (N,S)HC and (N,Se)HC complexes, respectively.

Docking studies of $\text{Ru}4^{\text{Y}}$ ($\text{Y} = \text{NBn}, \text{S}, \text{Se}$) to CatB indicated that the complexes are likely to form adducts with residues Cys29 and His199 simultaneously, which are part of the catalytic pocket and active site of the protein.⁹⁰ Other ruthenium complexes have previously been reported to interact with Cys29.¹⁸ For $\text{Ru}4^{\text{Se}}$, two different poses binding Cys29:His199 were observed (SI Fig. 19), which could explain the higher cytotoxicity of $\text{Ru}4^{\text{Se}}$ (Fig. 7).

Conclusions

Unconventional chalcogen-containing azolyldiene (N,Y)HC ($\text{Y} = \text{NR}, \text{O}, \text{S}, \text{Se}$) metal complexes based on (benz)oxazole, (benzo)thiazole and benzoselenazole were successfully synthesised, including the first reported transition metal selenazolyldiene complexes. The electronic and steric properties of these unconventional, chalcogen-based carbene ligands were investigated. The ligands were found to be overall weaker donors with enhanced π -acceptor ability, which could prove useful in the synthesis of low-valent or main group complexes and potentially favouring catalytic reactions benefiting from electron-deficient metal centres. The cytotoxicity of the (N,Y)HC complexes was evaluated against ovarian cancer cells. Distinct trends in cytotoxicity emerged, depending on the metal centre. In the platinum complexes, substitution of the alkylated nitrogen in the azolyldiene ligand for a chalcogen atoms decreased cytotoxicity following the trend (N,N)HC > (N,O)HC > (N,S)HC. For gold and ruthenium, the (N,Se)HC complexes, being the only reported examples of this class, were more cytotoxic than, in order, the respective (N,O)HC, (N,N)HC, and (N,S)HC analogues, suggesting a new avenue for putative metallocarbene anticancer drug candidates. In many cases, the complexes were able to overcome cisplatin-related resistance. Mechanistic and structural studies were performed *in vitro*, *in cellulo*, *in crystallo*, and *in silico*, revealing that incorporation of a chalcogen atom into the heterocyclic scaffold can modulate biological targets, activity and biomolecular interactions of the complexes. These findings highlight the potential of

unconventional chalcogen azolyldiene ligands as tuneable scaffolds to fine-tune the biological activity of metal complexes.

Author contributions

J. R.-dG. conceived the idea and led the project. J. R.-dG., P. M. F. P., A. N. V. and L. E. K. F. conducted the synthesis and characterisation of the proligands and metal complexes. I. L. S. and K. G. carried out the biological experiments. F. F.-T. and R. S. collected and processed the single-crystal X-ray data. F. K. performed the cell fluorescence microscopy measurements and K. G. solved the protein crystal structures. All authors contributed to the discussion of the results and revision of the manuscript. P. J. D. directed and supervised the project.

Conflicts of interest

There are no conflicts to declare.

Data availability

The data supporting this article has been included in the supplementary information (SI). See DOI: <https://doi.org/10.1039/d5sc05555e>.

CCDC 2130715, 2270445–2270450, 2271662, 2395164 and 2395165 contain the supplementary crystallographic data for this paper.^{91a–j}

Protein crystallographic data for the adducts of HEWL with $\text{Ru}4^{\text{S}}$ and $\text{Ru}4^{\text{Se}}$ has been deposited at the PDB under accession numbers 9HTI and 9HTJ, respectively.^{92a,b}

Additional data generated in this study is openly available at <https://doi.org/10.5281/zenodo.16159145>.

Acknowledgements

This research has been funded by the Swiss National Science Foundation and the École Polytechnique Fédérale de Lausanne. The Mass Spectrometry and Elemental Analysis service, and the Nuclear Magnetic Resonance platform of EPFL are acknowledged for their support. We thank Dr S. A. Tellite and Dr R. Laplaza for the fruitful DFT discussions, and Prof. C. A. Davey for advice on structural biology. The authors acknowledge Dr F. Pojer and Dr A. N. Larabi of the Protein Production and Structure Core Facility and the staff at the Biomolecular Screening Facility of EPFL. We are grateful for the encouragement of Dr R. J. Somerville, Dr D. Savary, and Dr R.-C. Turnell-Ritson, and the support of Dr A. Egurbide-Sifre and Dr H. Solé-Àvila.

Notes and references

- 1 M. N. Hopkinson, C. Richter, M. Schedler and F. Glorius, *Nature*, 2014, **510**, 485–496.
- 2 P. Bellotti, M. Koy, M. N. Hopkinson and F. Glorius, *Nat. Rev. Chem.*, 2021, **5**, 711–725.
- 3 K. M. Hindi, M. J. Panzner, C. A. Tessier, C. L. Cannon and W. J. Youngs, *Chem. Rev.*, 2009, **109**, 3859–3884.



- 4 L. Oehninger, R. Rubbiani and I. Ott, *Dalton Trans.*, 2013, **42**, 3269–3284.
- 5 I. Ott, in *Advances in Inorganic Chemistry*, Elsevier, 2020, vol. 75, pp. 121–148.
- 6 S. A. Patil, A. P. Hoagland, S. A. Patil and A. Bugarin, *Future Med. Chem.*, 2020, **12**, 2239–2275.
- 7 Q. Zhao, B. Han, C. Peng, N. Zhang, W. Huang, G. He and J. Li, *Med. Res. Rev.*, 2024, **44**, 2194–2235.
- 8 S. Zhao, Z. Yang, G. Jiang, S. Huang, M. Bian, Y. Lu and W. Liu, *Coord. Chem. Rev.*, 2021, **449**, 214217.
- 9 P. Heringova, J. Woods, F. S. Mackay, J. Kasparkova, P. J. Sadler and V. Brabec, *J. Med. Chem.*, 2006, **49**, 7792–7798.
- 10 T. Kishimoto, Y. Yoshikawa, K. Yoshikawa and S. Komeda, *Int. J. Mol. Sci.*, 2019, **21**, 34.
- 11 J. Kasparkova, *Nucleic Acids Res.*, 2004, **32**, 5546–5552.
- 12 M. Skander, P. Retailleau, B. Bourrié, L. Schio, P. Mailliet and A. Marinetti, *J. Med. Chem.*, 2010, **53**, 2146–2154.
- 13 M. Mora, M. C. Gimeno and R. Visbal, *Chem. Soc. Rev.*, 2019, **48**, 447–462.
- 14 A. Pratesi, C. Gabbiani, E. Michelucci, M. Ginanneschi, A. M. Papini, R. Rubbiani, I. Ott and L. Messori, *J. Inorg. Biochem.*, 2014, **136**, 161–169.
- 15 P. J. Barnard and S. J. Berners-Price, *Coord. Chem. Rev.*, 2007, **251**, 1889–1902.
- 16 H. Ghareeb and N. Metanis, *Chem. - Eur. J.*, 2020, **26**, 10175–10184.
- 17 B. Dominelli, J. D. G. Correia and F. E. Kühn, *J. Organomet. Chem.*, 2018, **866**, 153–164.
- 18 A. Casini, C. Gabbiani, F. Sorrentino, M. P. Rigobello, A. Bindoli, T. J. Geldbach, A. Marrone, N. Re, C. G. Hartinger, P. J. Dyson and L. Messori, *J. Med. Chem.*, 2008, **51**, 6773–6781.
- 19 N. Aggarwal and B. F. Sloane, *Proteomics: Clin. Appl.*, 2014, **8**, 427–437.
- 20 A. Catalano, A. Mariconda, M. S. Sinicropi, J. Ceramella, D. Iacopetta, C. Saturnino and P. Longo, *Antibiotics*, 2023, **12**, 365.
- 21 K. J. Kilpin, S. Crot, T. Riedel, J. A. Kitchen and P. J. Dyson, *Dalton Trans.*, 2014, **43**, 1443–1448.
- 22 C. Vanucci-Bacqué, M. Wolff, B. Delavaux-Nicot, A. M. Abdallah, S. Mallet-Ladeira, C.-L. Serpentine, F. Bedos-Belval, K. W. Fong, X. Y. Ng, M. L. Low, E. Benoist and S. Fery-Forgues, *Dalton Trans.*, 2024, **53**, 11276–11294.
- 23 B. Bertrand, A. S. Romanov, M. Brooks, J. Davis, C. Schmidt, I. Ott, M. O'Connell and M. Bochmann, *Dalton Trans.*, 2017, **46**, 15875–15887.
- 24 H. V. Huynh, *The Organometallic Chemistry of N-heterocyclic Carbenes*, Wiley, 1st edn, 2017.
- 25 Y. Gothe, I. Romero-Canelón, T. Marzo, P. J. Sadler, L. Messori and N. Metzler-Nolte, *Eur. J. Inorg. Chem.*, 2018, **2018**, 2461–2470.
- 26 A. Gutiérrez, M. C. Gimeno, I. Marzo and N. Metzler-Nolte, *Eur. J. Inorg. Chem.*, 2014, **2014**, 2512–2519.
- 27 E. O. Fischer, D. Himmelreich, R. Cai, H. Fischer, U. Schubert and B. Zimmer-Gasser, *Chem. Ber.*, 1981, **114**, 3209–3219.
- 28 J. Zhang, T. Li, X. Li, A. Lv, X. Li, Z. Wang, R. Wang, Y. Ma, R. Fang, R. Szostak and M. Szostak, *Commun. Chem.*, 2022, **5**, 60.
- 29 K. E. Horner and P. B. Karadakov, *J. Org. Chem.*, 2015, **80**, 7150–7157.
- 30 Z. Kelemen, O. Hollóczki, J. Oláh and L. Nyulászi, *RSC Adv.*, 2013, **3**, 7970.
- 31 M. A. A. Ibrahim and E. M. Z. Telb, *ACS Omega*, 2020, **5**, 21631–21640.
- 32 W. Wang, H. Zhu, S. Liu, Z. Zhao, L. Zhang, J. Hao and Y. Wang, *J. Am. Chem. Soc.*, 2019, **141**, 9175–9179.
- 33 Z. Alamiddine, S. Thany, J. Graton and J. Le Questel, *ChemPhysChem*, 2018, **19**, 3069–3083.
- 34 L. Vogel, P. Wonner and S. M. Huber, *Angew. Chem., Int. Ed.*, 2019, **58**, 1880–1891.
- 35 A. Chand, D. K. Sahoo, A. Rana, S. Jena and H. S. Biswal, *Acc. Chem. Res.*, 2020, **53**, 1580–1592.
- 36 K. Konidaris, A. Daolio, A. Pizzi, P. Scilabra, G. Terraneo, S. Quici, J. S. Murray, P. Politzer and G. Resnati, *Cryst. Growth Des.*, 2022, **22**, 4987–4995.
- 37 R. Rubbiani, I. Kitanovic, H. Alborzinia, S. Can, A. Kitanovic, L. A. Onambele, M. Stefanopoulou, Y. Geldmacher, W. S. Sheldrick, G. Wolber, A. Prokop, S. Wölfl and I. Ott, *J. Med. Chem.*, 2010, **53**, 8608–8618.
- 38 L. Oehninger, M. Stefanopoulou, H. Alborzinia, J. Schur, S. Ludewig, K. Namikawa, A. Muñoz-Castro, R. W. Köster, K. Baumann, S. Wölfl, W. S. Sheldrick and I. Ott, *Dalton Trans.*, 2013, **42**, 1657–1666.
- 39 J. M. Duelos and P. Haake, *Biochemistry*, 1974, **13**, 5358–5362.
- 40 T. Scattolin and S. P. Nolan, *Trends Chem.*, 2020, **2**, 721–736.
- 41 N. V. Tzouras, F. Nahra, L. Falivene, L. Cavallo, M. Saab, K. Van Hecke, A. Collado, C. J. Collett, A. D. Smith, C. S. J. Cazin and S. P. Nolan, *Chem.-Eur. J.*, 2020, **26**, 4515–4519.
- 42 E. Chardon, G. Dahm, G. Guichard and S. Bellemin-Lapponnaz, *Organometallics*, 2012, **31**, 7618–7621.
- 43 M. Bouché, B. Vincent, T. Achard and S. Bellemin-Lapponnaz, *Molecules*, 2020, **25**, 3148.
- 44 T. M. Gilbert and T. Ziegler, *J. Phys. Chem. A*, 1999, **103**, 7535–7543.
- 45 L. Falivene and L. Cavallo, *Coord. Chem. Rev.*, 2017, **344**, 101–114.
- 46 N. Y. S. Lam, D. Truong, H. Burmeister, M. V. Babak, H. U. Holtkamp, S. Movassaghi, D. M. Ayine-Tora, A. Zafar, M. Kubanik, L. Oehninger, T. Söhnle, J. Reynisson, S. M. F. Jamieson, C. Gaiddon, I. Ott and C. G. Hartinger, *Inorg. Chem.*, 2018, **57**, 14427–14434.
- 47 Z. İ. Oruç, L. Gök, H. Türkmen, O. Şahin, O. Büyükgüngör and B. Çetinkaya, *J. Organomet. Chem.*, 2016, **807**, 36–44.
- 48 P. Scilabra, G. Terraneo and G. Resnati, *Acc. Chem. Res.*, 2019, **52**, 1313–1324.
- 49 H. V. Huynh, *Chem. Rev.*, 2018, **118**, 9457–9492.
- 50 R. Dorta, E. D. Stevens, N. M. Scott, C. Costabile, L. Cavallo, C. D. Hoff and S. P. Nolan, *J. Am. Chem. Soc.*, 2005, **127**, 2485–2495.
- 51 D. J. Nelson and S. P. Nolan, *Chem. Soc. Rev.*, 2013, **42**, 6723.



- 52 G. Meng, L. Kakalis, S. P. Nolan and M. Szostak, *Tetrahedron Lett.*, 2019, **60**, 378–381.
- 53 K. Verlinden, H. Buhl, W. Frank and C. Ganter, *Eur. J. Inorg. Chem.*, 2015, **2015**, 2416–2425.
- 54 A. Liske, K. Verlinden, H. Buhl, K. Schaper and C. Ganter, *Organometallics*, 2013, **32**, 5269–5272.
- 55 J. Mathew and C. H. Suresh, *Inorg. Chem.*, 2010, **49**, 4665–4669.
- 56 H. Jacobsen, A. Correa, A. Poater, C. Costabile and L. Cavallo, *Coord. Chem. Rev.*, 2009, **253**, 687–703.
- 57 C. B. Aakeroy, D. L. Bryce, G. R. Desiraju, A. Frontera, A. C. Legon, F. Nicotra, K. Rissanen, S. Scheiner, G. Terraneo, P. Metrangolo and G. Resnati, *Pure Appl. Chem.*, 2019, **91**, 1889–1892.
- 58 A. S. Lundemba, D. D. Bibelayi, P. V. Tsalu, P. A. Wood, J. Cole, J. S. Kayembe and Z. G. Yav, *Cryst. Struct. Theory Appl.*, 2021, **10**, 57–69.
- 59 L. Falivene, R. Credendino, A. Poater, A. Petta, L. Serra, R. Oliva, V. Scarano and L. Cavallo, *Organometallics*, 2016, **35**, 2286–2293.
- 60 A. C. Hillier, W. J. Sommer, B. S. Yong, J. L. Petersen, L. Cavallo and S. P. Nolan, *Organometallics*, 2003, **22**, 4322–4326.
- 61 M. Xu, D. J. McCanna and J. G. Sivak, *J. Pharmacol. Toxicol. Methods*, 2015, **71**, 1–7.
- 62 A. K. Nath, X. Shi, D. L. Harrison, J. E. Morningstar, S. Mahon, A. Chan, P. Sips, J. Lee, C. A. MacRae, G. R. Boss, M. Brenner, R. E. Gerszten and R. T. Peterson, *Cell Chem. Biol.*, 2017, **24**, 565–575.e4.
- 63 T. Marzo, D. Cirri, C. Gabbiani, T. Gamberi, F. Magherini, A. Pratesi, A. Guerri, T. Biver, F. Binacchi, M. Stefanini, A. Arcangeli and L. Messori, *ACS Med. Chem. Lett.*, 2017, **8**, 997–1001.
- 64 C. Scolaro, A. Bergamo, L. Brescacin, R. Delfino, M. Cocchietto, G. Laurency, T. J. Geldbach, G. Sava and P. J. Dyson, *J. Med. Chem.*, 2005, **48**, 4161–4171.
- 65 I. Buß, D. Garmann, M. S. Galanski, G. Weber, G. V. Kalayda, B. K. Keppler and U. Jaehde, *J. Inorg. Biochem.*, 2011, **105**, 709–717.
- 66 T. Mahata, A. Kanungo, S. Ganguly, E. K. Modugula, S. Choudhury, S. K. Pal, G. Basu and S. Dutta, *Angew. Chem., Int. Ed.*, 2016, **55**, 7733–7736.
- 67 P. Nowak-Sliwinska, J. R. Van Beijnum, A. Casini, A. A. Nazarov, G. Wagnières, H. Van Den Bergh, P. J. Dyson and A. W. Griffioen, *J. Med. Chem.*, 2011, **54**, 3895–3902.
- 68 G. Lv, L. Guo, L. Qiu, H. Yang, T. Wang, H. Liu and J. Lin, *Dalton Trans.*, 2015, **44**, 7324–7331.
- 69 P. Langer, *Synlett*, 2022, **33**, 728–736.
- 70 N. Talarek, J. Petit, E. Gueydon and E. Schwob, in *DNA Replication*, ed. S. Vengrova and J. Dalgaard, Springer New York, New York, NY, 2015, vol. 1300, pp. 105–112.
- 71 S. Yang, D. Luo, N. Li, C. Li, S. Tang and Z. Huang, *Biochemistry*, 2020, **59**, 4344–4352.
- 72 C. S. Allardyce and P. J. Dyson, *Dalton Trans.*, 2016, **45**, 3201–3209.
- 73 S. Rodríguez-Enríquez, D. X. Robledo-Cadena, S. C. Pacheco-Velázquez, J. L. Vargas-Navarro, J. A. Padilla-Flores, T. Kaambre and R. Moreno-Sánchez, *PLoS One*, 2024, **19**, e0309331.
- 74 R. F. S. Lee, A. Chernobrovkin, D. Rutishauser, C. S. Allardyce, D. Hacker, K. Johnsson, R. A. Zubarev and P. J. Dyson, *Sci. Rep.*, 2017, **7**, 1590.
- 75 M. P. Sullivan, M. K. Nieuwoudt, G. A. Bowmaker, N. Y. S. Lam, D. Truong, D. C. Goldstone and C. G. Hartinger, *Chem. Commun.*, 2018, **54**, 6120–6123.
- 76 L. Messori and A. Merlino, *Dalton Trans.*, 2014, **43**, 6128.
- 77 M. P. Sullivan, M. Cziferszky, I. Tolbatov, D. Truong, D. Mercadante, N. Re, R. Gust, D. C. Goldstone and C. G. Hartinger, *Angew. Chem., Int. Ed.*, 2021, **60**, 19928–19932.
- 78 A. Annunziata, M. E. Cucciolito, M. Di Ronza, G. Ferraro, M. Hadiji, A. Merlino, D. Ortiz, R. Scopelliti, F. Fadaei Tirani, P. J. Dyson and F. Ruffo, *Organometallics*, 2023, **42**, 952–964.
- 79 B. Y. T. Lee, M. P. Sullivan, E. Yano, K. K. H. Tong, M. Hanif, T. Kawakubo-Yasukochi, S. M. F. Jamieson, T. Soehnel, D. C. Goldstone and C. G. Hartinger, *Inorg. Chem.*, 2021, **60**, 14636–14644.
- 80 M. P. Sullivan, M. Groessl, S. M. Meier, R. L. Kingston, D. C. Goldstone and C. G. Hartinger, *Chem. Commun.*, 2017, **53**, 4246–4249.
- 81 Z. Adhikarsan, G. Palermo, T. Riedel, Z. Ma, R. Muhammad, U. Rothlisberger, P. J. Dyson and C. A. Davey, *Nat. Commun.*, 2017, **8**, 14860.
- 82 S. L. Dürr, A. Levy and U. Rothlisberger, *Nat. Commun.*, 2023, **14**, 2713.
- 83 J. Jumper, R. Evans, A. Pritzel, T. Green, M. Figurnov, O. Ronneberger, K. Tunyasuvunakool, R. Bates, A. Židek, A. Potapenko, A. Bridgland, C. Meyer, S. A. A. Kohl, A. J. Ballard, A. Cowie, B. Romera-Paredes, S. Nikolov, R. Jain, J. Adler, T. Back, S. Petersen, D. Reiman, E. Clancy, M. Zielinski, M. Steinegger, M. Pacholska, T. Berghammer, S. Bodenstein, D. Silver, O. Vinyals, A. W. Senior, K. Kavukcuoglu, P. Kohli and D. Hassabis, *Nature*, 2021, **596**, 583–589.
- 84 E. Ortega-Carrasco, A. Lledós and J.-D. Maréchal, *J. Comput. Chem.*, 2014, **35**, 192–198.
- 85 M. L. A. Hakkennes, F. Buda and S. Bonnet, *J. Chem. Inf. Model.*, 2023, **63**, 7816–7825.
- 86 G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. Goodsell and A. J. Olson, *J. Comput. Chem.*, 2009, **30**, 2785–2791.
- 87 H.-C. Tai, R. Brodbeck, J. Kasparkova, N. J. Farrer, V. Brabec, P. J. Sadler and R. J. Deeth, *Inorg. Chem.*, 2012, **51**, 6830–6841.
- 88 K. Fritz-Wolf, S. Urig and K. Becker, *J. Mol. Biol.*, 2007, **370**, 116–127.
- 89 B. Mirković, M. Renko, S. Turk, I. Sosič, Z. Jevnikar, N. Obermajer, D. Turk, S. Gobec and J. Kos, *ChemMedChem*, 2011, **6**, 1351–1356.
- 90 J. Schmitz, E. Gilberg, R. Löser, J. Bajorath, U. Bartz and M. Gütschow, *Bioorg. Med. Chem.*, 2019, **27**, 1–15.
- 91 (a) CCDC 2130715: Experimental Crystal Structure Determination, 2025, DOI: [10.5517/ccdc.csd.cc29j5rs](https://doi.org/10.5517/ccdc.csd.cc29j5rs); (b)



- CCDC 2270445: Experimental Crystal Structure Determination, 2025, DOI: [10.5517/ccdc.csd.cc2g6l5g](https://doi.org/10.5517/ccdc.csd.cc2g6l5g); (c) CCDC 2270446: Experimental Crystal Structure Determination, 2025, DOI: [10.5517/ccdc.csd.cc2g6l6h](https://doi.org/10.5517/ccdc.csd.cc2g6l6h); (d) CCDC 2270447: Experimental Crystal Structure Determination, 2025, DOI: [10.5517/ccdc.csd.cc2g6l7j](https://doi.org/10.5517/ccdc.csd.cc2g6l7j); (e) CCDC 2270448: Experimental Crystal Structure Determination, 2025, DOI: [10.5517/ccdc.csd.cc2g6l8k](https://doi.org/10.5517/ccdc.csd.cc2g6l8k); (f) CCDC 2270449: Experimental Crystal Structure Determination, 2025, DOI: [10.5517/ccdc.csd.cc2g6l9l](https://doi.org/10.5517/ccdc.csd.cc2g6l9l); (g) CCDC 2270450: Experimental Crystal Structure Determination, 2025, DOI: [10.5517/ccdc.csd.cc2g6lbn](https://doi.org/10.5517/ccdc.csd.cc2g6lbn); (h) CCDC 2271662: Experimental Crystal Structure Determination, 2025, DOI: [10.5517/ccdc.csd.cc2g7vf0](https://doi.org/10.5517/ccdc.csd.cc2g7vf0); (i) CCDC 2395164: Experimental Crystal Structure Determination, 2025, DOI: [10.5517/ccdc.csd.cc2ldccr](https://doi.org/10.5517/ccdc.csd.cc2ldccr); (j) CCDC 2395165: Experimental Crystal Structure Determination, 2025, DOI: [10.5517/ccdc.csd.cc2ldcds](https://doi.org/10.5517/ccdc.csd.cc2ldcds).
- 92 (a) J. Romano-deGea, K. Lau and P. J. Dyson, Adduct formed during the incubation of dichloro(3-benzylbenzoselenazol-2-ylidene)(eta6-p-cymene)ruthenium(II) with HEWL, 9HTI, 2026, DOI: [10.2210/pdb9HTI/pdb](https://doi.org/10.2210/pdb9HTI/pdb); (b) J. Romano-deGea, K. Lau and P. J. Dyson, Adduct formed during the incubation of dichloro(3-benzylbenzothiazol-2-ylidene)(eta6-p-cymene)ruthenium(II) with HEWL, 9HTJ, 2026, DOI: [10.2210/pdb9HTJ/pdb](https://doi.org/10.2210/pdb9HTJ/pdb).

